Tissue repair and ulcer/wound healing - Institut Pasteur Euroconference: molecular mechanisms, therapeutic targets and future directions.
Braddock
Martin
M
AstraZeneca plc, Disease Science Section, Discovery Biosciences Division, Loughborough, Leicestershire, UK. martin.braddock@astrazeneca.com
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D002921:Cicatrix / Q000188:drug therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000276:immunology; D000069285:Infliximab; D039041:Integrin alpha4beta1 / Q000627:therapeutic use; D007371:Interferon-gamma / Q000627:therapeutic use; D000069442:Natalizumab; D020932:Nerve Growth Factor / Q000235:genetics / Q000627:therapeutic use; D051381:Rats; D012756:Sheep; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000628:therapy; D014945:Wound Healing / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D039041:Integrin alpha4beta1; D000069442:Natalizumab; C505731:fontolizumab; D007371:Interferon-gamma; D020932:Nerve Growth Factor; D000069285:Infliximab; C456519:visilizumab